Green-lighted by the FDA, Halozyme Therapeutics Inc. plans to start by the end of 2016's first quarter the phase III push with PEGPH20, a pegylated form of the firm's recombinant human hyaluronidase, in patients with metastatic pancreatic cancer – and the trial design, which could allow for approval based on either progression-free survival (PFS) or overall survival (OS) endpoints, has analysts enthused.